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In this study, we examined the immune response during gonococcal infection to the individual transferrin
binding proteins by using a quantitative enzyme-linked immunosorbent assay (ELISA). Recombinant trans-
ferrin binding protein A (rTbpA) and rTbpB were purified under nondenaturing conditions for use as ELISA
antigens. Sera and secretions from culture-positive individuals were analyzed for antibodies to rTbpA and
rTbpB and compared to samples from individuals with no history of gonococcal infection. Although antibodies
to both rTbpA and rTbpB were detected in serum, in most cases the antibody levels were not significantly
different from those measured in the control population. Also, previous history of gonococcal infection did not
increase antibody levels in serum, suggesting the lack of an anamnestic response. Analysis of secretion samples
revealed antibody levels that were generally below the limits of detection in our assay. Overall, this study
demonstrated a paucity of systemic and local antibody responses to rTbps as a result of natural infection and
represents a baseline over which a protective antibody response will have to be generated in order to develop
an efficacious gonococcal vaccine.
Neisseria gonorrhoeae, the causative agent of the sexually
transmitted disease (STD) gonorrhea, is one of the most com-
mon sexually transmitted pathogens worldwide. In the United
States, an estimated 361,700 cases were reported in 2001 (9);
however, this number is likely an underrepresentation due to
incomplete reporting and the high prevalence of asymptomatic
infections (9, 26). Gonorrhea manifests as urethritis in men
and as endocervicitis and/or urethritis in women. Ascension to
the upper genital tract can occur in both sexes; in males this
can result in epididymitis or prostatitis. In females, ascension
can result in pelvic inflammatory disease, from which compli-
cations such as infertility, fallopian tube scarring, and subse-
quent ectopic pregnancy can occur. Disseminated gonococcal
infection can also result from infection, although this outcome
is less common. One of the hallmarks of this disease is a
mucopurulent discharge associated with symptomatic infec-
tion. Microscopic examination of the discharge reveals that it is
characterized by large numbers of polymorphonuclear leuko-
cytes associated with extracellular and intracellular diplococci.
Although a robust inflammatory response ensues during symp-
tomatic infection, no apparent protective immunity is devel-
oped following infection, as shown in a male human challenge
study (44) and by the high incidence of recidivism among
patients attending sexually transmitted disease clinics (4, 21,
35, 40).
The search for a vaccine against gonorrhea has been largely
disappointing. In human vaccine trials, partially lysed gono-
cocci, purified pilin, and purified porin were shown to be im-
munogenic, but all failed to elicit protection upon subsequent
natural exposure (7, 19, 46). The lack of protective immunity is
likely due, in part, to the capacity of many gonococcal surface
antigens to undergo high-frequency phase and antigenic vari-
ation (38). With the increasing emergence of drug-resistant
strains (9) and the disturbing finding that human immunode-
ficiency virus transmission is increased with concurrent gono-
coccal infection (11, 27), the search for effective vaccine anti-
gens has become more urgent. The gonococcal transferrin
binding proteins (Tbps) have garnered interest as potential
vaccine antigens due to their surface accessibility, sequence
conservation, and ubiquitous expression in all strains studied to
date (12, 13, 34, 39, 42). Expression of the transferrin receptor
has been shown to be necessary for establishment of infection
in humans (16). In the closely related species Neisseria menin-
gitidis, murine vaccine studies using the Tbps as vaccine anti-
gens demonstrated that mice immunized with TbpA or TbpA
plus TbpB were protected upon subsequent lethal challenge
(49).
Immunity to meningococcal infection is thought to develop
as a result of the generation of bactericidal antibodies follow-
ing carriage and/or infection. Convalescent-phase sera from
individuals recovering from meningococcal infections contain
antibodies specific for the Tbps (1, 29, 33); however, it is not
known whether these antibodies contribute to protection. By
contrast, little is known about the immunogenicity of the Tbps
during natural gonococcal infections. However, recent studies
investigating the antibody response to the whole gonococcus
indicate that local and systemic antibody responses during and
following gonococcal infection were not robust compared to
the level of antibodies present in a control population (21, 22).
These observations are consistent with those of recent inves-
tigations described by Boulton and Gray-Owen (8) document-
ing down regulation of T-cell activation as a result of interac-
tion between Opa-expressing gonococci and CEACAM1-
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expressing T cells. By down regulating T cells, the gonococcus
could potentially limit the antibody response by inhibiting T-
cell helper functions. These findings are consistent with the
observation that individuals recovering from gonococcal dis-
ease do not develop immunity to further episodes (4, 21, 35,
40).
In the present study, we measured antibody levels to the
individual gonococcal Tbps in serum and secretions during
natural infections. Previous studies conducted by Hedges et al.
(21, 22) illustrated a paucity of antibodies to the whole gono-
coccus; however, these studies failed to evaluate specific anti-
body responses to individual antigens. Furthermore, gonococ-
cal cells used as antigens by Hedges et al. were not grown in
iron-depleted media. Consequently, iron-repressible proteins
were not maximally expressed, and hence a portion of the
antibody repertoire may not have been evaluated in the pre-
vious studies. To fully characterize the specific immune re-
sponse to the individual Tbps during natural infection, we
expressed and purified recombinant Tbps (rTbps) and used
them as antigens in quantitative enzyme-linked immunosor-
bent assays (ELISAs). We analyzed sera and secretions from
infected patients and compared the antibody levels to those
detected in naïve individuals.
MATERIALS AND METHODS
Specimen collection and processing. Twenty serum samples from a previous
longitudinal study of N. gonorrhoeae infection at an STD clinic in Wilson County,
North Carolina (17), were screened in the present study. Additional serum
samples and genital secretions were collected prospectively for this study from
subjects attending the STD clinic of the Wake County Department of Health and
Human Services in Wake County, North Carolina. The samples were collected at
the time of patient presentation, and infection with N. gonorrhoeae was subse-
quently confirmed by culture by using routine laboratory methods. Sera from
adult volunteers with no history of gonorrhea were also used as uninfected
controls. Clinical histories were obtained, including previous gonococcal infec-
tion and the time since last infection; however, no specific information was
obtained regarding the onset or duration of symptoms. Informed consent was
obtained from all subjects and volunteers, and research was approved by the
Institutional Review Boards of Virginia Commonwealth University and the Uni-
versity of North Carolina at Chapel Hill. Research protocols complied with all
relevant federal guidelines and institutional policies.
Sera from peripheral venous blood was aliquoted and frozen at 70°C. Semen
was allowed to liquefy at room temperature for 10 to 30 min, aliquoted, and
frozen at 70°C until analysis. After being thawed, the semen was centrifuged at
1,000  g for 5 min, and antibody concentrations were measured in the super-
natant seminal plasma. Swabs containing cervical mucous were resuspended in
0.5 ml of phosphate-buffered saline (PBS) and frozen at 70°C. After being
thawed, the cervical secretions were centrifuged at 1,000  g for 5 min, and
antibody concentrations were measured in the supernatant fluid.
Construction of expression plasmids. The tbpA expression plasmid,
pUNCH412, was described previously (14). The tbpB expression plasmid,
pVCU705, was constructed by PCR amplification of the genomic copy of tbpB
from gonococcal strain FA19 by using a proofreading Taq polymerase (Platinum
Pfx; Invitrogen). The forward primer, oVCU170 (CATATGAACAATCCATTG
GTGAATCAGG), contained an NdeI site (shown in bold) and amplified the
tbpB native signal sequence. The reverse primer, oVCU172 (CTCGAGTTTCA
CAAGCTTTTGGC), contained an XhoI restriction site (shown in bold) and
encoded the terminal lysine of TbpB from gonococcal strain FA19. The PCR
product was ligated into the pET-22b() expression vector (Novagen). The
resultant plasmid, pVCU705, contained the full-length tbpB gene under control
of a T7 promoter, as well as a region encoding a six-histidine tag immediately 3
of tbpB. The expression host for both plasmids was the Escherichia coli strain
BL21(DE3) (Novagen).
Recombinant protein expression and purification. One-liter cultures contain-
ing Luria-Bertani broth (LB) (pH 7.5), 1% glucose, and 500 g of carbenicil-
lin/ml were inoculated with recombinant E. coli strains and grown at 37°C with
shaking. When the cultures reached an optical density at 600 nm of 0.4 to 0.6,
they were centrifuged for 15 min at 6,000  g to pellet the bacteria. The
supernatants were decanted, and 1 liter of fresh LB containing glucose and
carbenicillin was added. IPTG (isopropyl--D-thiogalactopyranoside) was added
at 1 mM for 3 h at 37°C to induce protein expression. After induction, the
cultures were removed and bacterial cells were pelleted and stored at 80°C.
For purification, the pellets were thawed on ice and resuspended in buffer
containing 100 mM Tris (pH 8.0)–0.5 M NaCl (Tris buffer). Elugent (Calbio-
chem) was added to a final concentration of 2%. A protease inhibitor cocktail
(Calbiochem) was added, along with lysozyme, DNase, and RNase to promote
cell lysis and to reduce viscosity. Solubilized preparations were subjected to high
speed centrifugation at 39,000  g for 40 min. For rTbpA purification, the super-
natant was added to a transferrin affinity matrix (30); for rTbpB purification, the
supernatant was added to a nickel-nitriloacetic affinity resin (QIAGEN). The
rTbpA-transferrin column was washed with 20-bed volumes of Tris buffer and
then eluted by using 50 mM glycine (pH 2.0)–0.5 M NaCl–1% octylglucoside
(n-octyl--D-glucopyranoside; Calbiochem). The eluted proteins were immedi-
ately neutralized in collection tubes containing 1 M Tris (pH 8.0). rTbpB was
processed similarly except that the column was washed with 20-bed volumes of 50
mM NaH2PO4–300 mM NaCl–20 mM imidazole (pH 8.0) and eluted by using a
buffer containing 50 mM NaH2PO4–300 mM NaCl–250 mM imidazole (pH 8.0).
Amino-terminal sequencing of rTbpB. For N-terminal sequencing of rTbpB,
samples were prepared as previously described (30). Sequencing was performed
by Midwest Analytical, Inc. (St. Louis, Mo.)
Western blotting and solid-phase transferrin-binding assays. Western blot-
ting was performed by using iron-stressed N. gonorrhoeae strain MCV601 (30),
iron stressed N. meningitidis strain FAM2 (47), or purified recombinant proteins
transferred onto nitrocellulose (Schleicher & Schuell). To detect TbpA, the blots
were probed with either a polyclonal rabbit serum raised against a denatured
TbpA (15) or a polyclonal serum raised against recombinant TbpA. The latter
serum was elicited by immunization of New Zealand White Elite rabbits (Co-
vance Research Products, Denver, Pa.) with recombinant TbpA, purified as
described above. For TbpB detection, polyclonal rabbit serum raised against
recombinant TbpB (kindly provided by Christopher Thomas and P. Frederick
Sparling) or, alternatively, peroxidase-conjugated human transferrin (HRP-
Tf; Jackson Immunoresearch) was used. The blots were developed with ni-
troblue tetrazolium–5-bromo-4-chloro-3-indolyl phosphate (BCIP) or with
Opti-4CN (Bio-Rad). For solid-phase transferrin binding assays, purified
rTbpA or rTbpB was applied to nitrocellulose supports, which were subse-
quently probed with HRP-Tf. Dot blots were developed by using the color-
imetric substrate Opti-4CN.
ELISAs. Serum and mucosal secretions were screened for antibodies specific
to rTbpA and rTbpB. TbpA, TbpB, or tetanus toxoid (Calbiochem) was diluted
in coating buffer (0.1 M NaCl, 0.05 M boric acid, 0.0012 M sodium tetraborate
decahydrate, pH 8.2) to a concentration of 1 g/ml, and then the proteins were
applied to individual wells in 96-well microtiter plates (Nunc) overnight at 4°C.
Following binding, the plates were washed with PBS containing 0.15% Tween 20
(Sigma) and then blocked for 2 h with PBS containing Tween 20 and 5% skim
milk to reduce nonspecific binding. Sera or secretion samples were diluted in
PBS with Tween 20 and 5% skim milk, and the dilutions were added to the plates
and incubated overnight at 4°C. The plates were again washed and blocked as
described above, and then goat anti-human alkaline phosphatase-conjugated
antibodies (Jackson Immunoresearch and Southern Biotechnology Associates)
were used to detect antigen-specific immunoglobulin G (IgG), IgA, or IgM. For
each plate, a standard curve was generated by using anti-human immunoglobu-
lins of known isotypes (Jackson Immunoresearch and Southern Biotechnology
Associates). Known concentrations of human Igs (Sigma and Jackson Immu-
noresearch) were added and serially diluted to generate the standard curve. The
plates were developed with p-nitrophenylphosphate substrate (Sigma) in carbon-
ate buffer (0.05 M sodium carbonate, 1 mM MgCl2, pH 9.8), and the reaction was
allowed to proceed until sufficient color developed. The reactions were stopped
with the addition of 2 M NaOH, and the plates were analyzed using a Multiskan
Ascent microplate reader (Thermo Labsytems, Helsinki, Finland). Ig concentra-
tions in the samples were interpolated from the standard curve by using Ascent
software (Thermo Labsystems). The samples were analyzed at multiple dilutions
when applicable to confirm parallelism with the standard curve.
Statistics. Statistical analysis was performed by using NCSS 2000/Pass 2000
statistics software. Data analysis between groups included the Mann-Whitney U
test and the Kolmogorov-Smirnov test. Determination of the most appropriate
test depended on data normality and the variance between the groups being
measured. A P value of 0.05 was considered significant.
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RESULTS AND DISCUSSION
We expressed and purified recombinant TbpA and TbpB
under nondenaturing conditions (Fig. 1) and utilized the over-
expressed proteins as ELISA antigens in order to evaluate sera
and secretions for the presence of Tbp-specific antibodies. The
purification conditions used in this study enabled us to obtain
recombinant protein that retained ligand-binding properties
similar to those of the native proteins (Fig. 1C and F). This
condition was an important aspect of the analysis, as antibodies
recognizing conformational epitopes could still be measured. It
is believed that conformational epitopes represent the vast
majority of epitopes in proteins (2), and it has been shown that
the use of denatured proteins in ELISAs can reduce the sen-
sitivity of the assay (23, 31).
Expression and purification of rTbpB resulted in two major
bands when analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and Western blotting (Fig. 1D
and E). Both bands reacted with a rabbit anti-TbpB serum, and
both bound horseradish peroxidase (HRP)-transferrin, although
the smaller species did so weakly (Fig. 1E). Because both protein
bands reacted with an anti-histidine tag antibody (data not
shown), the target for which was located at the carboxy terminus
of the protein, the difference in their apparent molecular weights
was expected to be the result of alterations of the amino terminus.
N-terminal sequencing of the smaller species confirmed that it
was indeed a truncated form of TbpB, 110 amino acids shorter in
length than the mature TbpB protein, initiated with the sequence
MYTSP. Since both protein species were TbpB derived, we con-
tinued with these recombinant protein preparations as ELISA
target antigens.
To quantify levels of antibodies specific for rTbpA and rTbpB,
we examined sera from 27 males and 14 females who were
culture positive for gonorrhea in a quantitative ELISA. The
antibody concentrations of infected individuals were compared
to those of a control group of adult volunteers with no history
of gonococcal disease and of individuals attending an STD
clinic who were culture negative for gonorrhea without a prior
history of gonococcal disease. Both genders were included in
the control group. Concentrations of IgG, IgM, and IgA in
serum were analyzed for specificity to TbpA and TbpB (Fig. 2).
Although we were able to measure antibodies to rTbpA and
rTbpB, the concentrations were not dramatically different
from those detected among individuals in the negative control
group. Statistical analysis of the antibody concentrations in
serum detected in infected women indicated that only TbpB-
specific IgG and IgA Ig classes were significantly different from
those detected in the control group (P  0.03 for both isotypes,
as determined by the Kolmogorov-Smirnov test) (Fig. 2B).
This statistical correlation occurred only in women, and the
median antibody concentration detected among this group of
infected individuals was only slightly higher than that deter-
mined within the uninfected control group. This finding was
corroborated in Western blots in which a subset of the female
sera was screened (Fig. 3). Western blot reactivities against
TbpB, whether in purified form or in the context of total-
membrane preparations, were greater when screened with fe-
male sera than with male or uninfected control sera (Fig. 3A
and C). One explanation for the detection of higher antibody
concentrations in females could be gleaned from the nature of
gonococcal infection. Typically, women have higher rates of
asymptomatic infection than do men (6, 26); additionally,
women often suffer longer latent periods before symptoms of
gonorrhea appear (25). This longer latent period may give the
immune system more time to mount a response before treat-
ment is sought (10). However, clearly many of these samples
from infected females fell well within the antibody levels of the
controls, with only a few individuals having slightly higher
antibody titers than the controls (Fig. 2B). The more signifi-
cant response elicited toward TbpB than towards TbpA could
be explained by the relative immunogenicity of these two mol-
ecules in the context of a natural infection. The greater se-
quence variability seen among TbpBs than among TbpAs (12,
13) is consistent with the hypothesis that TbpB is more immu-
nogenic than TbpA.
Because both the infected individuals and the negative controls
had similar serum antibody levels specific for rTbpA and rTbpB,
we explored the possibility that both were the result of cross-
reactive antibodies elicited during meningococcal carriage. Hicks
et al. demonstrated that antibodies elicited following meningo-
coccal colonization were cross-reactive with the N. gonorrhoeae
antigens, pili and H.8 (24). We performed similar analyses using
iron-stressed membrane proteins from meningococcal strain
FAM2 and an lbp mutant of gonococcal strain FA19, MCV601
FIG. 1. Expression and purification of rTbps. (A) Coomassie blue-
stained SDS-polyacrylamide gel containing rTbpA protein. Lane 1 con-
tains the soluble fraction after detergent solubilization of induced E. coli.
Lanes 2 through 7 represent rTbpA purification fractions. Lane 2 contains
the column flowthrough fraction after overnight incubation with a human
transferrin-bound affinity column. Lane 3 contains the wash fraction.
Lanes 4 through 7 contain purified rTbpA column elution fractions. Mo-
lecular weight standards (MWM) are indicated at the left. (B) Western
blot of the above SDS-PAGE probed with an anti-TbpA antibody. The
positions of molecular weight standards are indicated on the left.
(C) Solid-phase transferrin binding assay of purified rTbpA probed with
HRP-transferrin (1 g/ml). Lane 1 contains duplicate spots of purified
rTbpA. Lane 2 contains duplicate spots of buffer only. (D) Coomassie
blue-stained SDS-PAGE containing rTbpB protein. Lane 1 contains a
whole-cell lysate of IPTG-induced E. coli. Lane 2 contains the soluble
fraction of IPTG-induced, detergent-solubilized E. coli. Lanes 3 through
6 represent rTbpB purification fractions. Lane 3 contains the flowthrough
after overnight incubation with a nickel-affinity resin. Lane 4 contains the
wash fraction. Lanes 5 through 6 contain purified rTbpB fractions. Mo-
lecular weight standards (MWM) are indicated at the left. (E) Western
blots of purified rTbpB. Panel 1 was probed with an anti-TbpB antibody.
Panel 2 was probed with HRP-transferrin (1 g/ml). (F) Solid-phase
transferrin binding assay of purified rTbpB probed with HRP-transferrin
(1 g/ml). Lane 1 contains duplicate spots of rTbpB. Lane 2 contains
duplicate spots of buffer only.
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(Fig. 3A and B). The meningococcal strain chosen for this analysis
expressed a TbpB of the low-molecular-weight class. This family
of proteins is quite diverse from the high-molecular-weight class,
to which all gonococcal TbpBs belong (13), and thus represents a
stringent test for cross-reactivity. The analysis presented in Fig. 3
demonstrates that although most of the individuals screened ap-
peared to have antibodies reactive against meningococcal TbpA,
TbpB-specific antibodies were more reactive against the gonococ-
cal protein. Thus, based on these reactivities, we cannot defini-
tively establish whether the antibodies detected were elicited by
meningococcal carriage or by the current gonococcal infection.
However, we can conclude that if the antibodies were elicited as
a result of colonization with N. meningitidis, the colonizing strains
likely expressed a TbpB of the high-molecular-weight isotype,
which is more similar to TbpBs expressed by N. gonorrhoeae and
more frequently encountered in nature (42). Moreover, we can
also conclude that the presence of these antibodies in serum did
not protect the subjects from acquisition of N. gonorrhoeae ex-
pressing a cross-reactive TbpB protein.
To correlate the Tbp-specific serum antibodies detected in
this study with what would constitute a protective antibody
level, we analyzed randomly selected serum samples for the
presence and concentration of antibodies against a common
vaccine antigen, tetanus toxoid (Fig. 4). The immune response
elicited against tetanus toxoid is robust (3), and we reasoned
that everyone in our study population had been immunized
with this antigen at some time previously. Moreover, the pres-
ence of tetanus toxoid-specific antibodies would establish that
the infected individuals in this study were capable of mounting
a humoral immune response. Since we had no documentation
FIG. 2. IgG, IgM, and IgA antibody responses in serum. (A) Antibody responses against rTbpA. (B) Antibody responses against rTbpB. The
infected groups are divided into those with a first gonococcal infection (filled symbols) and those with at least one prior episode of gonorrhea (open
symbols). The control group is divided into volunteer lab personnel (filled symbols) and individuals attending an STD clinic who were culture
negative with no previous history of gonococcal disease (open symbols). The horizontal bars indicate median values. Differences between the
groups were compared with the Mann-Whitney U test or the Kolmogorov-Smirnov test where appropriate. Note the logarithmic scales.
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of immunization histories on the study subjects and since tet-
anus toxoid antibodies are known to decrease over time (18,
48), we obtained serum from an individual who had recently
been immunized as a positive control for this experiment. Even
those individuals whose antibody responses to tetanus toxoid
were modest compared to those of the control individual had
antitetanus toxoid antibody concentrations 5- to 10-fold higher
than those of either TbpA- or TbpB-specific antibodies. The
greatest differential between anti-Tbp and anti-tetanus toxoid
antibodies detected among this study population was 100-fold.
We analyzed one individual’s serum antibody responses fol-
lowing four separate episodes of gonorrhea over a period of 6
months (Fig. 5) to determine if recurrent gonococcal infection
increased the serum antibody response to TbpA or TbpB.
Although there was a small, transient increase recorded during
the second infection, overall Tbp-specific antibody levels re-
mained relatively constant, highlighting the lack of an anam-
nestic antibody response.
We analyzed cervical mucus from females and seminal
plasma from males to determine if secretory Tbp-specific an-
tibodies were correlated with antibody concentrations in se-
rum. Total Ig levels were determined (Table 1), and we found
no significant differences in total antibody levels between the
female groups. In the men, there was a significant difference in
total IgA concentrations between the infected individuals and
the controls, with the controls having higher levels of IgA (P 
0.014, as determined by the Kolmogorov-Smirnov test). How-
ever, caution must be taken in interpreting this data since only
a small number of male uninfected control samples were avail-
able for analysis.
FIG. 3. Western blot analysis of patient sera. (A) Western blot of a
total-membrane preparation of iron-stressed N. gonorrhoeae probed with
patient sera diluted 1:150. (B) Western blot of a total membrane prepa-
ration of iron-stressed N. meningitidis probed with the same dilution of
patient sera as in panel A. (C) Western blot of purified gonococcal TbpA
and TbpB probed with patient sera diluted at 1:100. Lanes 1 and 16 are
negative controls with no antibody. Lane 2 was probed with an anti-TbpA
antibody. Lanes 3 through 5 are female control sera. Lanes 6 and 7 are
male control sera. Lanes 8 and 9 are sera from females infected with
gonorrhea for the first time. Lanes 10 and 11 contain sera from females
with at least one prior gonococcal infection. Lane 12 contains sera from a
male infected with gonorrhea for the first time. Lanes 13 and 14 contain
sera from males with at least one prior gonococcal infection. Lane 15 was
probed for TbpB by using HRP-transferrin.
FIG. 4. Comparison of serum IgG responses to rTbpA, rTbpB, and
tetanus toxoid. Patients’ identification numbers and genders are indi-
cated on the x axis. Antibodies to rTbpA or rTbpB were not measured
in the control serum (C/M). Note the logarithmic scale.
FIG. 5. Longitudinal serum antibody response. Serum antibody re-
sponses to rTbpA and rTbpB were detected from an infected male
individual following four separate episodes of gonorrhea over a
6-month period. Following the initial infection, subsequent infections
occurred at 1, 3, and 6 months. Note the logarithmic scale.
TABLE 1. Total genital tract immunoglobulin levels from
uninfected and infected volunteers
Sample type and
antibody class
Median Ig levels (g/ml) (range [n])
No previous history Current Infection
Cervical mucus
IgG 15.6 (0.1–178.6 [14]) 6.1 (0.3–89.8 [11])
IgM 0.3 (0.0–64.0 [14]) 4.6 (0.1–34.5 [11])
IgA 9.6 (0.2–121.5 [14]) 8 (0.0–88.5 [11])
Seminal plasma
IgG 75.7 (49.5–187.0 [4]) 75.5 (34.6–727.5 [9])
IgM 1.2 (0.4–7.5 [4]) 3.5 (1.1–47.0 [9])
IgA 79.3 (54.4–80.1 [4]) 42.5a (27.0–348.7 [9])
a P  0.05 compared with results for uninfected controls (as determined by the
Kolmogorov-Smirnov test).
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While we were able to detect Tbp-specific antibodies in the
sera from all individuals tested, we were unable to detect any
Tbp-specific antibodies in the secretions from any individual
infected with N. gonorrhoeae. This observation suggests that
circulating antibodies in the serum were not of sufficient con-
centration to allow transudation from serum to genital mucosa.
Also, local production of antibodies was not induced to either
Tbp protein during infection, as shown by the lack of detect-
able IgA against either antigen. It is striking that the total
antibody concentrations in these infected females was low,
even though there was an active infection occurring at the time
of sample collection. In general, the males had much greater
total antibody titers than the females, yet we were unable to
detect antigen-specific responses in any of the males. To rule
out the possibility of interfering substances in the secretions,
we performed an ELISA by using secretion specimens spiked
with TbpA-specific rabbit antiserum. We detected no de-
creased antibody-antigen recognition in the presence of secre-
tions from either males or females (data not shown).
One secretion sample from a culture-negative, female STD
clinic attendee contained measurable secretory antibodies specific
for TbpA (Table 2). These antibodies, of both IgA and IgM
classes, appeared to be locally produced, as evidenced by higher
IgA concentrations in the secretions than in the serum samples
(Table 2). Furthermore, if these antibodies were from serum
transudation, we should have been able to detect rTbpA-specific
IgG, but we were unable to do so. We were also unable to
measure detectable anti-TbpB antibodies in this individual, which
could be the result of poor antigenic cross-reactivity between
gonococcal TbpBs (12, 13). More importantly, why did this sub-
ject have anti-TbpA antibodies if she was not infected? One
possible explanation is that she did have a gonococcal infection
but was culture negative. Another possibility is that this individual
was infected with N. gonorrhoeae but the infection was in the
latent or eclipse phase, during which culture of viable organisms
is difficult. The detection of high concentrations of TbpA-specific
IgM in the secretions is consistent with the suggestion that the
infection was likely recently acquired or in its early stages (37).
Previous studies have shown modest secretory antibody re-
sponses to the whole gonococcus in both males and females (21,
22, 35, 36, 45) and to specific antigens in vaginal fluids (28, 32). So
why were we unable to measure genital antibody responses to the
Tbps? One possible explanation for the lack of a genital-tract
immune response to these antigens during a natural infection is
that these proteins may be hidden from the immune system. The
bacterium may coat itself with human transferrin in an effort to
hide the Tbps from immune surveillance. Also, these antigens
may not be immunogenic in the context of a whole organism, or
other diversional antigens may elicit relatively greater antibody
responses (28, 32). Another interesting possibility relates to the
finding that N. gonorrhoeae has the ability to down regulate T cells
through Opa-CEACAM1 interactions (8). Down regulating T
cells could, in turn, suppress antibody production against T-cell-
dependent protein antigens. This effect could also inhibit the
development of memory responses to these antigens, which is
consistent with our finding that multiple episodes of gonococcal
disease did not correlate with an increase in Tbp-specific serum
antibody levels.
Conclusions. Although anti-Tbp antibodies were detected in
the sera of patients suffering from gonococcal disease, the
response was not robust compared to that elicited against
tetanus toxoid, a known protective antigen. Furthermore, the
response did not appear to be significantly increased with ad-
ditional gonococcal exposure, indicating the lack of an anam-
nestic response. Because infected individuals and the unin-
fected controls had similarly low levels of Tbp-specific serum
antibodies, we suggest that pre-existing antibodies, possibly
elicited by meningococcal carriage, while cross-reactive, were
not protective in the context of a gonococcal infection. We also
demonstrated a complete lack of detectable antibodies specific
for either TbpA or TbpB in the secretions of any infected
individual. This finding has important implications for vaccine
development. It is clear from these data that gonococcal infec-
tion did not elicit Tbp-specific antibodies in the genital tract,
which would likely be the first line of defense. However, elic-
itation of a mucosal immune response in the genital tract by
using a purified antigen, such as the Tbps, could be protective
even though these same antigens presented in the context of a
live gonococcus do not elicit a protective response. Intranasal
vaccination has proven a good strategy in the generation of
antibody responses in the genital tracts and sera of rodents,
primates, and humans (5, 20, 43). A recent study showed pro-
tection from gonococcal colonization of mice following intra-
nasal immunization using gonococcal outer membrane prepa-
rations (41). Studies in our laboratory are currently under way
to test whether induction of an antibody response in the genital
tract by vaccination with TbpA and/or TbpB could prevent
colonization and/or multiplication in an exposed individual.
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